Oropharyngeal Cancer Survivors Research Articles

Trends of oral and oropharyngeal cancer survival over five decades in 3267 patients treated in a single institution

The objective of this study was to analyze the influence of changes in the treatment on the prognosis of patients treated over 44 years in a single institution. The 5-decade trends in treatment approach and 5-year survival of 3267 patients treated between 1953 and 1997 were analyzed. An increase was observed in primary surgical treatment and its association with radiotherapy. In the 1950s, 29.1% of the patients were treated by surgery, 54.5% by radiotherapy and 16.4% by combined treatment; in the 1990s, these proportions were 39.7, 9.7 and 50.6%, respectively ( P<0.001). There was a significant increase in the 5-year survival rates from 28.7% for patients treated in the 1950s to 43.2% in the 1990s ( P<0.001). The changes in treatment approach for oral and oropharyngeal cancer over the last 5 decades, with an increase of surgical treatment and its combination with radiotherapy significantly improved the survival rates.

Quality of life 2–10 years after combined treatment for advanced oral and oropharyngeal cancer

This study reports the findings of an evaluation of Quality of Life (QOL) in long-term survivors of advanced oral and oropharyngeal cancer treated with preoperative chemoradiotherapy followed by surgery (combined treatment=multimodal therapy). All patients had T2–T4 tumours and all received locoregional radical resection and simultaneous microvascular reconstruction. From 1990 to 1998, 181 patients have been treated at the University Hospital of Cranio-Maxillofacial and Oral Surgery in Vienna. 100 (55%) of these patients were alive and free of disease in 2000. Sixty-seven of them completed the EORTC questionnaires QLQ 30 and QLQ H&N 35. We found these questionnaires to be very good tools for determining QOL, which constitutes part of the therapeutic success. Patients tended to report good to very good QOL. A comparison between groups according to clinical data was conducted as well as a group comparison of patients who claimed especially high or low QOL in the questionnaires.It was found that combined treatment not only offers the best chances for survival, but also allows a subsequent QOL, that is comparable to other forms of therapy.

Combined modality treatment of locally advanced oral and oropharyngeal cancer following primary radiotherapy with and without taxol radiosenzitization

AIM: To determine the effect of radiosensitization with Taxol and multimodality treatments on the survival of advanced oral and oropharyngeal cancer. Patients, methods: 56 patients with St. III-IV oral or oropharyngeal cancer were treated with external beam radiotherapy; 26 of them were sensitized by low-dose paxlitaxel and 30 were irradiated traditionally. The median follow up was 23 months (17-36). Endpoints of the study were: response to radiotherapy, progression-free and overall survival and the results of surgery and chemotherapy following radiation. RESULTS: 73.3% (41/56) of treatments resulted in CR or PR with median 10 months (0-33) progression-free and 14 months (4-33) overall survival. There was no significant difference between the radiosensitized and traditional radiotherapy group (p=0.6). The survival was significantly influenced by the stage of tumor and the response to primary radiotherapy. Seven (38.9%) of 16 patients treated also by either surgery or chemotherapy for recurrent or residual disease are free of cancer, 6 (35%) alive with tumor and 5 (26.1%) died with median survivals of 21, 20.5 and 18 months, respectively. Those treated only with radiotherapy with or without sensitization are free of cancer in 31.6%, alive with cancer 5.3%, died 63.2%. CONCLUSION: There were significant correlation between tumor stage, response to radiotherapy and combined modality treatment, and surival. The radiosensitizing effect of Taxol was not obvious so far, it may be apparent in the future by analyzing the long term survival data.